Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 1;38(2):267-269.
doi: 10.1097/QAD.0000000000003765. Epub 2023 Dec 20.

The impact of obesity on doravirine exposure in people with HIV

Leena Zino  1 , Lianne P M van Bussel  1 , Rick Greupink  1 , Manon Marneef  2 , David M Burger  1 , Angela Colbers  1
Affiliations

The impact of obesity on doravirine exposure in people with HIV

Leena Zino et al. AIDS. .

Abstract

Obesity incidence is increasing among people with HIV. Doravirine is a recommended first-line antiretroviral drug in many countries with no data from people with obesity. This study investigates the exposure of doravirine 100 mg standard dose in obese versus normal weight patients using clinical data combined with physiologically based pharmacokinetic modelling. Results from both approaches showed an elevated doravirine exposure during obesity, yet within the safety range of doravirine with no need for dose modification.

PubMed Disclaimer

References

    1. Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. HIV and antiretroviral therapy-related fat alterations . Nat Rev Dis Primers 2020; 6:48.
    1. FDA. Pifeltro (doravirine) muli-Discipline Review/Summary, Clinical, Nonclinical . 2018 [cited 31 March 2022]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210806Orig1s000,... . [Accessed 01 May 2023]
    1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation . World Health Organ Tech Rep Ser, 2000. 894: p. i–xii, 1–253.
    1. Yee KL, Ouerdani A, Claussen A, de Greef R, Wenning L. Population pharmacokinetics of doravirine and exposure-response analysis in individuals with HIV-1 . Antimicrob Agents Chemother 2019; 63:e02502-18.
    1. Bukkems VE, van Hove H, Roelofsen D, Freriksen JJM, van Ewijk-Beneken Kolmer EWJ, Burger DM, et al. Prediction of maternal and fetal doravirine exposure by integrating physiologically based pharmacokinetic modeling and human placenta perfusion experiments . Clin Pharmacokinet 2022; 61:1129–1141.

MeSH terms